Herbert Ira Hurwitz, MD

Adjunct Professor in the Department of Medicine
Campus mail 439 Seeley-Mudd Bldg, 10 Bryan Searle Drive, Duke University M, Durham, NC 27710
Phone (919) 681-6006
Email address hurwi004@mc.duke.edu

Particular Clinical Interests and Skills: Phase I clinical trials involving new anti cancer drugs; drug combinations; and combinations of new drugs with radiation; cancers of the GI system

Education and Training

  • Clinical Oncology Fellow, Medicine, Johns Hopkins University, 1992 - 1996
  • Medical Resident, Medicine, Michael Reese Hospital & Medical Center, 1988 - 1991
  • M.D., Thomas Jefferson University, 1988

Publications

Garcia, J., H. I. Hurwitz, A. B. Sandler, D. Miles, R. L. Coleman, R. Deurloo, and O. L. Chinot. “Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.” Cancer Treatment Reviews 86 (June 1, 2020). https://doi.org/10.1016/j.ctrv.2020.102017.

Full Text

Alvarez Secord, Angeles, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, et al. “Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1288–96. https://doi.org/10.1158/1078-0432.CCR-19-0226.

PMID
31919136
Full Text

Strickler, John H., Christel N. Rushing, Donna Niedzwiecki, Abigail McLeod, Ivy Altomare, Hope E. Uronis, S David Hsu, et al. “A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.” Bmc Cancer 19, no. 1 (November 1, 2019): 1032. https://doi.org/10.1186/s12885-019-6234-8.

PMID
31675952
Full Text

Clarke, Jeffrey Melson, Gerard C. Blobe, John H. Strickler, Hope Elizabeth Uronis, S Yousuf Zafar, Michael Morse, Evan Dropkin, et al. “A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).” Cancer Chemother Pharmacol 84, no. 4 (October 2019): 909–17. https://doi.org/10.1007/s00280-019-03916-0.

PMID
31444620
Full Text

Bendell, Johanna C., Tamara Sauri, Antonio Cubillo Gracián, Rafael Alvarez, Carlos López-López, Pilar García-Alfonso, Maen Hussein, et al. “The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).” Oncologist, September 30, 2019. https://doi.org/10.1634/theoncologist.2019-0291.

PMID
31570519
Full Text

Burzykowski, Tomasz, Elisabeth Coart, Everardo D. Saad, Qian Shi, Dirkje W. Sommeijer, Carsten Bokemeyer, Eduardo Díaz-Rubio, et al. “Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer.” Jama Netw Open 2, no. 9 (September 4, 2019): e1911750. https://doi.org/10.1001/jamanetworkopen.2019.11750.

PMID
31539075
Full Text

Coker, Shodeinde A., Herbert I. Hurwitz, Sunil Sharma, Ding Wang, Pierre Jordaan, Juan Pablo Zarate, and Lionel D. Lewis. “The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.” Cancer Chemother Pharmacol 84, no. 2 (August 2019): 383–92. https://doi.org/10.1007/s00280-019-03880-9.

PMID
31187169
Full Text

Innocenti, Federico, Chen Jiang, Alexander B. Sibley, Stefanie Denning, Amy S. Etheridge, Dorothy Watson, Donna Niedzwiecki, et al. “An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).” Pharmacogenet Genomics 29, no. 6 (August 2019): 123–31. https://doi.org/10.1097/FPC.0000000000000375.

PMID
30889042
Full Text

Hurwitz, Herbert I., Benjamin R. Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz-Josef Lenz, Howard S. Hochster, et al. “Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).” Oncologist 24, no. 7 (July 2019): 921–32. https://doi.org/10.1634/theoncologist.2018-0344.

PMID
30552157
Full Text

Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.

PMID
30895346
Full Text

Pages